Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Assets: 2012-2024

Historic Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $697.6 million.

  • Agios Pharmaceuticals' Non-Current Assets fell 50.86% to $352.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.6 million, marking a year-over-year decrease of 50.86%. This contributed to the annual value of $697.6 million for FY2024, which is 575.42% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Non-Current Assets stood at $697.6 million for FY2024, which was up 575.42% from $103.3 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Non-Current Assets ranged from a high of $697.6 million in FY2024 and a low of $103.3 million during FY2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Non-Current Assets value was $405.9 million (recorded in 2022), while the average stood at $402.3 million.
  • In the last 5 years, Agios Pharmaceuticals' Non-Current Assets slumped by 74.56% in 2023 and then skyrocketed by 575.42% in 2024.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Non-Current Assets stood at $216.3 million in 2020, then spiked by 72.70% to $373.5 million in 2021, then rose by 8.69% to $405.9 million in 2022, then tumbled by 74.56% to $103.3 million in 2023, then skyrocketed by 575.42% to $697.6 million in 2024.